Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cinvanti Generic Name & Formulations
Legal Class
Rx
General Description
Aprepitant 130mg/18mL; emulsion for IV inj or infusion after dilution; contains egg lecithin, ethanol.
Pharmacological Class
Substance P/NK1 receptor antagonist.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Cinvanti Indications
Indications
In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.
Limitations of Use
Not studied for treating established nausea and vomiting.
Cinvanti Dosage and Administration
Adult
Give with dexamethasone and 5-HT3 antagonist (see full labeling). Administer approx. 30mins prior to chemotherapy. Give by IV inj over 2mins (do not dilute) or by IV infusion over 30mins. Moderately emetogenic (3-day regimen): 100mg IV on Day 1, then oral aprepitant 80mg on Days 2 and 3. Moderately to highly emetogenic (single-dose regimen): 130mg IV on Day 1.
Children
Not established.
Cinvanti Contraindications
Contraindications
Concomitant pimozide.
Cinvanti Boxed Warnings
Not Applicable
Cinvanti Warnings/Precautions
Warnings/Precautions
Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms experienced with previous use. Severe hepatic impairment: monitor. Elderly. Pregnancy: avoid. Nursing mothers.
Cinvanti Pharmacokinetics
See Literature
Cinvanti Interactions
Interactions
See Contraindications. Monitor concomitant CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine). Avoid concomitant moderate-to-strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, diltiazem) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its oral dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods during and for 1 month after last dose).
Cinvanti Adverse Reactions
Adverse Reactions
Headache, fatigue, eructation, infusion-site reactions; anaphylaxis.
Cinvanti Clinical Trials
See Literature
Cinvanti Note
Not Applicable
Cinvanti Patient Counseling
See Literature
